November 22, 2010 -- Aoxing Pharmaceutical announced the SFDA granted a Manufacturing License to its joint venture, Hebei Aoxing API Pharmaceutical Company, Ltd. Aoxing expects to begin commercial production at the JV next year. The JV’s first product will be the API for naloxone hydrochloride, an opioid antagonist administered to counteract the effects of narcotic drug overdose. More details....
